Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APH 1501

Next Previous
Drug Profile

APH 1501

Alternative Names: APH-1501; APH-1501-5; nanoCDBTM

Latest Information Update: 29 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aphios Corporation
  • Class Antiepileptic drugs; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cyclohexenes; Cyclopropanes; Drug withdrawal therapies; Ethers; Ketones; Morphinans; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Resorcinols; Small molecules
  • Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Opioid receptor antagonists; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Opioid-related disorders

Most Recent Events

  • 25 Jul 2025 APH 1501 is available for licensing as of 25 Jul 2025. https://aphios.com/partnering/partnering-overview/
  • 25 Jul 2025 Early research in Opioid-related disorders in USA (unspecified route) (Aphios Pharma pipeline, July 2025)
  • 27 Jul 2021 Aphios plans phase II trial in Opioid-related disorders (NCT03813095)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top